Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$1.58M, compared with $494K a year earlier. Trailing-twelve-month accounts payables was $1.7M. Over 3 fiscal years it compounded at +26.8% a year.
Context
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$1.58M or moves back toward the trailing-twelve-month quarterly average of $425.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 3.78M USD
- Year-over-year change
- +1483.2%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.78M | +1483.2% |
| FY2024 | 2024-12-31 | (273K) | -96.4% |
| FY2023 | 2023-12-31 | (139K) | -107.5% |
| FY2022 | 2022-12-31 | 1.85M | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Payables vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 accounts payables of $1.7M is the 4th largest of the 11 companies compared; the peer median is $326.92K.
- Its year-over-year change of +38.1% is the 5th highest of 11, against a peer median of +0.4%.
- Over three fiscal years its annual growth of +26.8% compares with a peer median of +22.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $16.07M | -193.4% | — | 9.5% | |
| LTM Mar 2026 | $2.4M | +1061.2% | +48.0% | 4.8% | |
| LTM Mar 2026 | $2.31M | -48.2% | -70.5% | 1.5% | |
| LTM Mar 2026 | $1.7M | +38.1% | +26.8% | — | |
| LTM Mar 2026 | $1.2M | -56.1% | -3.2% | — | |
| LTM Mar 2026 | $1M | +148.6% | — | 4.6% | |
| LTM Mar 2026 | $796K | -35.7% | — | 0.4% | |
| LTM Mar 2026 | $671K | -192.8% | — | — | |
| LTM Mar 2026 | $456.35K | +226.0% | — | 91.3% | |
| LTM Mar 2026 | $448K | +36.6% | +70.0% | — | |
| LTM Mar 2026 | $197.49K | +121.5% | — | — | |
| Peer median (excluding NVCT) | $326.92K | +0.4% | +22.4% | 4.7% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.89M | 1.71M | 4.71M | 4.86M | 1.35M |
| Change in Working Capital | 1.49M | 3.82M | 1.74M | 1.9M | 4.4M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.85M | (139K) | (273K) | 3.78M |
| Other Working Capital | 1.49M | 1.97M | 1.88M | 2.17M | 625K |
| Other Non-Cash Items | 0 | 0 | (139K) | 0 | 4.68M |
| Operating Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.25M | 31.88M | 5.29M | 12.04M | 29.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.07M) | 9.8M | (382K) | 0 |
| Financing Cash Flow | 15.25M | 27.81M | 15.09M | 11.65M | 29.11M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.74M | 14.25M | (867K) | (593K) | 13.1M |
| Free Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.